Cantitate/Preț
Produs

BNF 84


en Paperback – 13 sep 2022
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 84) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.
Citește tot Restrânge

Preț: 43398 lei

Preț vechi: 51367 lei
-16% Nou

Puncte Express: 651

Preț estimativ în valută:
8308 8544$ 6892£

Cartea nu se mai tipărește

Doresc să fiu notificat când acest titlu va fi disponibil:

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780857114327
ISBN-10: 0857114328
Pagini: 1880
Dimensiuni: 148 x 210 x 44 mm
Greutate: 1.08 kg
Ediția:84 ed
Editura: Pharmaceutical Press

Descriere

he British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 84) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 84 edition include:

New monographs for:

  • Aspaveli® [pegcetacoplan] for paroxysmal nocturnal haemoglobinuria
  • Givlaari® [givosiran] for acute hepatic porphyria
  • Jemperli® [dostarlimab] for endometrial cancer
  • Paxlovid® [nirmatrelvir with ritonavir] for COVID-19
  • Shingrix® [herpes-zoster vaccine (recombinant, adjuvanted)] for immunisation against herpes zoster (shingles)
  • Vazkepa® [icosapent ethyl] as an adjunct to statin in prevention of cardiovascular events in hyperlipidaemia
  • Vumerity® [diroximel fumarate] for multiple sclerosis
  • Xevudy® [sotrovimab] for COVID-19
  • Xofluza® [baloxavir marboxil] for post-exposure prophylaxis or treatment of influenza

MHRA advice on:

  • Amiodarone hydrochloride (Cordarone X®): reminder of risks of treatment and need for patient monitoring and supervision
  • Brolucizumab (Beovu®): updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion
  • Chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
  • Cladribine (Mavenclad®): new advice to minimise risk of serious liver injury
  • COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
  • Haloperidol (Haldol®): reminder of risks when used in elderly patients for the acute treatment of delirium
  • Hydroxychloroquine sulfate: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
  • Ivacaftor, tezacaftor, elexacaftor (Kaftrio®▼) in combination with ivacaftor (Kalydeco®): risk of serious liver injury; updated advice on liver function testing
  • Metformin hydrochloride: study shows no safety concerns in pregnancy
  • Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
  • Pregabalin (Lyrica®): findings of safety study on risks during pregnancy
  • Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome

Other significant changes include updated guidance on:

  • Antiplatelet drugs for transcatheter aortic valve implantation
  • Buprenorphine transdermal patch strengths and prescribing considerations
  • Maximum daily doses added for colecalciferol and ergocalciferol in the treatment of vitamin D deficiency
  • COVID-19 updated guidance in-line with UK Health Security Agency recommendations
  • Management of acute otitis media
  • New requirement to register patients onto Esketamine (Spravato®) Register and Alert system
  • Management of glaucoma and ocular hypertension
  • Immunisation schedule updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including human papillomavirus, influenza, and varicella-zoster vaccines
  • Individual monographs created for herpes-zoster vaccine (recombinant, adjuvanted), herpes-zoster vaccine, live, and varicella-zoster vaccine
  • Miconazole oral gel no longer licensed for treatment of intestinal candidiasis
  • Obstetrics: induction of labour
  • Phosphate imbalance
  • Potassium permanganate: inadvertent oral administration of potassium permanganate [National Patient Safety Alert advice]
  • Sex hormones: use of progestogens for the prevention of miscarriage
  • Smoking cessation

BNF 84 is an essential publication, it provides you with:

• Up-to-date information on prescribing, dispensing, and administering medicines

• Authoritative, independent guidance on best practice enabling you to select safe and effective medicines

• Information you know you can trust for quality, reliability, and independence

• Everything you need at your fingertips, all in one book